- Home
- ASTH
as 03-28-2025 4:00pm EST
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. Its operating segment is the healthcare delivery segment.
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | ALHAMBRA |
| Market Cap: | 1.7B | IPO Year: | N/A |
| Target Price: | $56.17 | AVG Volume (30 days): | 358.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.90 | EPS Growth: | -30.23 |
| 52 Week Low/High: | $23.12 - $63.20 | Next Earning Date: | 05-06-2025 |
| Revenue: | $2,034,540,000 | Revenue Growth: | 46.72% |
| Revenue Growth (this year): | 35.17% | Revenue Growth (next year): | 20.76% |
Latest Astrana Health Inc. Common Stock News
ASTH Breaking Stock News: Dive into ASTH Ticker-Specific Updates for Smart Investing
Argus Research
4 days ago
ASTH: Lowering target price to $25.00
Simply Wall St.
19 days ago
Insider Favorites For Growth In March 2025
Argus Research
25 days ago
ASTH: Lowering target price to $21.00
GuruFocus.com
a month ago
Astrana Health Inc (ASTH) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
PR Newswire
a month ago
Astrana Health, Inc. to Participate in Upcoming Investor Conferences
Argus Research
a month ago
ASTH: Lowering target price to $28.00
Investor's Business Daily
a month ago
CVS Health Stock Gets RS Rating Upgrade
Argus Research
a month ago
ASTH: Raising target price to $35.00
Compare ASTH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ASTH Astrana Health Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.